MedTrace Logo

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

NCT05575830 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2025-09-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in older people (\> 50 years) living with HIV (PLWH) compared to age-matched healthy adults over a 1-year period.

Conditions

  • RZV Vaccine (Shingrix ®)

Interventions

BIOLOGICAL

Recombinant Zoster Vaccine

Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

Sponsors & Collaborators

  • Calmy Alexandra

    lead OTHER

Principal Investigators

  • Alexandra Calmy, Prof. MD · University Hospitals of Geneva, Infectious disease department,

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-14
Primary Completion
2025-04-16
Completion
2026-03-31

Countries

  • France
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05575830 on ClinicalTrials.gov